Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates

By Nasdaq5 days ago

Esperion Therapeutics (ESPR) came out with a quarterly loss of $3.89 per share versus the Zacks Consensus Estimate of a loss of $3.76. This compares to loss of $2.26 per share a year ago. These figures are adjusted for non-recurring items.

Continue read on nasdaq.com